These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
    Author: Wong PY, Lee WH, Chao PH, Reiss RF, McGiff JC.
    Journal: J Biol Chem; 1980 Oct 10; 255(19):9021-4. PubMed ID: 6997309.
    Abstract:
    We have reported the identification of a metabolite of prostacyclin (PGI2) in the liver, 6-keto-PGE1, a substance having similar potency to PGI2 in its vascular and antiaggregative actions but differing in its greater stability. Either PGI2 or its inactive hydrolysis product, 6-keto-PGF1 alpha, can be enzymically transformed via the 9-hydroxyprostaglandin dehydrogenase pathway to 6-keto-PGE1. In this study, we demonstrated 9-OH prostaglandin dehydrogenase activity in the cytoplasmic fraction of human platelets by measuring the release of 3H from positin 9 using [9-3H]PGI2 and [9-3H]6-keto-PGF1 alpha as substrates. The enzyme was further purified by DEAE-cellulose, followed by Sephadex G-200, and finally by isoelectric focusing. The enzyme was found to have a pH optimum of 8.5 to 9.0 and an isoelectric point of 5.0. The molecular weight was estimated to be 60,000 by sodium dodecyl sulfate-gel electrophoresis. Enzymic activity was time- and concentration-dependent and required NAD+ as a cofactor. The activity of the purified enzyme was further confirmed by using a more stable form of PGI2, the methyl ester. Incubation of [11-3H]PGI2 methyl ester with the purified enzyme resulted in formation of [11-3H]6-keto-PGE1 methyl ester, which also inhibited platelet aggregation. Thus, 9-hydroxyprostaglandin dehydrogenase in platelets could be a major enzymic pathway for the transformation of PGI2, and perhaps 6-keto-PGF1 alpha, to 6-keto-PGE1. The possibility that the effects of prostacyclin on platelet aggregation are related to conversion to the biologically active metabolite, 6-keto-PGE1, should be considered.
    [Abstract] [Full Text] [Related] [New Search]